BTAI

Pre-mercato: 1.25

Bioxcel Therapeutics Inc (BTAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BTAI Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Bioxcel Therapeutics Inc

Healthcare (1106)

203-643-8060

555 LONG WHARF DRIVE, NEW HAVEN, CT

Prossima data di guadagno

Ultimi documenti SEC

BTAI's Discussions on Twitter

Compare BTAI vs TAK, ZTS, TEVA, HLN, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BTAI Bioxcel Therapeutics Inc	1.25	33.84M	642.00K	-69.90M	-57.62M	-7.152
TAK Takeda Pharmaceutical Co Adr	16.55	52.28B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.33B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.76B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	40.70B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.28B	3.18B	1.33B	1.04B	27.90

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-17	Iniziato	Rodman & Renshaw	Buy
2024-02-21	Downgrade	UBS	Buy → Neutral
2023-08-15	Downgrade	Mizuho	Buy → Neutral
2023-07-17	Downgrade	Guggenheim	Buy → Neutral
2023-03-10	Downgrade	Jefferies	Buy → Hold
2022-12-01	Aggiornamento	Goldman	Sell → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-06	Reiterato	BofA Securities	Buy
2021-11-15	Downgrade	Goldman	Neutral → Sell
2021-04-09	Iniziato	Berenberg	Buy
2021-02-01	Iniziato	UBS	Buy
2020-10-30	Iniziato	Goldman	Buy
2020-09-02	Iniziato	Jefferies	Buy
2020-08-17	Reiterato	H.C. Wainwright	Buy
2020-07-08	Reiterato	H.C. Wainwright	Buy
2020-06-04	Iniziato	Guggenheim	Buy
2020-04-01	Iniziato	BofA/Merrill	Buy
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-12	Iniziato	SunTrust	Buy

Mostra tutto

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Compare BTAI vs TAK, ZTS, TEVA, HLN, UTHR

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

BioXcel Shareholder Action Reminder - TMX Newsfile

BioXcel Shareholder Notice - TMX Newsfile

BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill

BTAI: IGALMI targets a vast at-home market for acute agitation, with launch readiness for 2027 - TradingView

Transcript : BioXcel Therapeutics, Inc.Special Call - marketscreener.com

BTAI (BioXcel Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares gain 7.48 percent on upbeat investor reaction.NCAV - Xã Thanh Hà

BTAI BioXcel Therapeutics Inc. gains 7.48 percent after posting narrower than expected Q4 2025 EPS results. - Cổng thông tin điện tử tỉnh Tây Ninh

BTAI Financials: Income Statement, Balance Sheet & Cash Flow | Bioxcel Therapeutics Inc - Stock Titan

BioXcel Therapeutics, Inc. Enters Fourth Amended and Restated Registration Rights Agreement With Oaktree Investors - Minichart

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - Sahm

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI in the At-Home Setting - 富途牛牛

BioXcel Therapeutics issues warrants to lenders as part of credit agreement amendment - Investing.com

Bioxcel Issues Warrants in Private Equity Financing Deal - TipRanks

BioXcel Therapeutics (NASDAQ: BTAI) grants 1,353,729 low-price warrants - Stock Titan

BioXcel to detail IGALMI launch strategy ahead of FDA decision By Investing.com - Investing.com Australia

H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns - Insider Monkey

BioXcel to detail IGALMI launch strategy ahead of FDA decision - Investing.com

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI) - The Globe and Mail

H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary D - GuruFocus

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm

BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada

BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia

Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn

BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com

BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada

BioXcel drug enters U.S. military-funded study for acute stress after trauma - Stock Titan

BTAI Technical Analysis & Stock Price Forecast - Intellectia AI

BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore

BTAI Should I Buy - Intellectia AI

BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus

H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa

H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo

FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa

FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - Sahm

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a BTAI